Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-11-13 00:33 | 2025-11-11 | GALT | GALECTIN THERAPEUTICS INC | 10X Fund, L.P. | 10% owner | SELL | $5.25 | 40,000 | $210,000 | 5,832,207 |
| 2025-11-13 00:01 | 2025-11-10 | GALT | GALECTIN THERAPEUTICS INC | LEWIS JOEL | Director, Officer | OPT+S | $6.03 | 1,867 | $11,252 | 832,592 |
| 2025-11-13 00:01 | 2025-11-10 | GALT | GALECTIN THERAPEUTICS INC | CALLICUTT JACK W | Officer | OPT+S | $6.03 | 5,291 | $31,884 | 7,614 |
| 2025-11-13 01:34 | 2025-11-10 | TRDA | Entrada Therapeutics, Inc. | BAKER BROS. ADVISORS LP | 10% owner | BUY | $7.60 | 178,044 | $1,352,582 | 4,664,924 |
| 2025-11-13 01:14 | 2025-11-10 | UTHR | UNITED THERAPEUTICS Corp | BENKOWITZ MICHAEL | Officer | OPT+S | $452.07 | 22,500 | $10,171,683 | 0 |
| 2025-11-13 01:13 | 2025-11-10 | UTHR | UNITED THERAPEUTICS Corp | EDGEMOND JAMES | Officer | OPT+S | $452.07 | 21,000 | $9,493,483 | 8,118 |
| 2025-11-13 00:31 | 2025-11-10 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $450.10 | 8,000 | $3,600,830 | 130 |
| 2025-11-13 02:00 | 2025-11-10 | ACAD | Acadia Pharmaceuticals Inc. | Daly James M | Director | SELL | $22.37 | 30,000 | $670,983 | 4,041 |
| 2025-11-13 02:50 | 2025-11-11 | CYTK | CYTOKINETICS INC | Kaye Edward M. MD | Director | OPT+S | $65.08 | 5,175 | $336,789 | 9,977 |
| 2025-11-11 00:37 | 2025-11-07 | REGN | REGENERON PHARMACEUTICALS, INC. | Pitofsky Jason | Officer | SELL | $651.43 | 431 | $280,766 | 4,233 |
| 2025-11-11 00:06 | 2025-11-06 | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Weiss Amir | Officer | SELL | $24.44 | 12,300 | $300,564 | 17,950 |
| 2025-11-11 01:42 | 2025-11-06 | ARQT | Arcutis Biotherapeutics Inc. | Edwards Larry Todd | Officer | SELL | $25.16 | 29,131 | $732,927 | 150,193 |
| 2025-11-11 01:33 | 2025-11-06 | BBIO | BridgeBio Pharma, Inc. | Kumar Neil | Director, Officer | SELL | $62.29 | 80,000 | $4,983,112 | 795,686 |
| 2025-11-11 01:41 | 2025-11-06 | ARQT | Arcutis Biotherapeutics Inc. | Burnett Patrick | Officer | OPT+S | $24.18 | 17,250 | $417,145 | 98,325 |
| 2025-11-11 01:21 | 2025-11-07 | ZOMDF | Zomedica Corp. | Klass Russell Kevin | Officer | BUY | $0.10 | 5,000 | $475 | 5,514,101 |
| 2025-11-11 00:54 | 2025-11-06 | QURE | uniQure N.V. | Gut Robert | Director | OPT+S | $27.26 | 31,434 | $856,881 | 40,145 |
| 2025-11-11 05:51 | 2025-11-07 | BNTC | Benitec Biopharma Inc. | SUVRETTA CAPITAL MANAGEMENT, LLC | Director, 10% owner | BUY | $13.50 | 1,481,481 | $19,999,994 | 1,819,812 |
| 2025-11-11 00:05 | 2025-11-06 | CTMX | CytomX Therapeutics, Inc. | McCarthy Sean A. | Director, Officer | SELL | $4.54 | 101,793 | $461,906 | 987,891 |
| 2025-11-11 00:09 | 2025-11-07 | EBS | Emergent BioSolutions Inc. | Dayal Sujata Tyagi | Director | SELL | $10.00 | 8,552 | $85,520 | 88,980 |
| 2025-11-11 03:14 | 2025-11-07 | LFVN | Lifevantage Corp | BEINDORFF MICHAEL A | Director | SELL | $6.93 | 36,000 | $249,581 | 56,413 |
| 2025-11-11 00:15 | 2025-11-06 | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | MIGNONE ROBERTO | Director | SELL | $24.11 | 200,000 | $4,821,880 | 495,000 |
| 2025-11-11 03:50 | 2025-11-07 | PAHC | PHIBRO ANIMAL HEALTH CORP | BENDHEIM JACK | Director, Officer, 10% owner | SELL | $45.09 | 41,823 | $1,885,619 | 20,577 |
| 2025-11-08 01:13 | 2025-11-06 | IONS | IONIS PHARMACEUTICALS INC | Birchler Brian | Officer | SELL | $76.17 | 8,000 | $609,379 | 48,826 |
| 2025-11-08 00:30 | 2025-11-05 | LQDA | Liquidia Corp | Saggar Rajeev | Officer | SELL | $27.00 | 71,381 | $1,927,287 | 176,549 |
| 2025-11-08 00:46 | 2025-11-06 | ZOMDF | Zomedica Corp. | Klass Russell Kevin | Officer | BUY | $0.08 | 253,007 | $20,241 | 5,509,101 |
| 2025-11-08 00:20 | 2025-11-07 | ARVN | Arvinas Inc. | Loomis David K | Officer | SELL | $9.89 | 230 | $2,275 | 31,697 |
| 2025-11-08 05:00 | 2025-11-07 | ROIV | Roivant Sciences Ltd. | Venker Eric | Officer | OPT+S | $20.22 | 200,000 | $4,044,000 | 1,504,959 |
| 2025-11-08 01:12 | 2025-11-05 | IONS | IONIS PHARMACEUTICALS INC | Geary Richard S | Officer | OPT+S | $75.69 | 34,639 | $2,621,816 | 59,657 |
| 2025-11-08 01:12 | 2025-11-03 | IONS | IONIS PHARMACEUTICALS INC | Geary Richard S | Officer | OPT+S | $75.05 | 1,680 | $126,091 | 59,657 |
| 2025-11-08 00:58 | 2025-11-06 | EVOK | Evoke Pharma Inc | Klein Roger M. | 10% owner | SELL | $10.65 | 9,000 | $95,885 | 125,000 |
| 2025-11-08 00:01 | 2025-11-05 | OCUL | OCULAR THERAPEUTIX, INC | Saroj Namrata | Officer | SELL | $10.74 | 25,865 | $277,790 | 174,135 |
| 2025-11-08 00:23 | 2025-11-06 | COLL | COLLEGIUM PHARMACEUTICAL, INC | Tupper Colleen | Officer | SELL | $40.53 | 30,000 | $1,215,753 | 126,667 |
| 2025-11-08 02:03 | 2025-11-06 | BBIO | BridgeBio Pharma, Inc. | DANIELS RONALD J | Director | OPT+S | $63.72 | 61,031 | $3,888,999 | 16,991 |
| 2025-11-08 00:20 | 2025-11-05 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | BATE KENNETH | Director | OPT+S | $484.30 | 16,575 | $8,027,354 | 2,627 |
| 2025-11-08 00:09 | 2025-11-05 | GALT | GALECTIN THERAPEUTICS INC | LEWIS JOEL | Director, Officer | OPT+S | $6.00 | 200 | $1,200 | 832,592 |
| 2025-11-08 00:07 | 2025-11-05 | GALT | GALECTIN THERAPEUTICS INC | CALLICUTT JACK W | Officer | OPT+S | $6.00 | 600 | $3,600 | 7,614 |
| 2025-11-08 01:10 | 2025-11-05 | CORT | CORCEPT THERAPEUTICS INC | Guyer William | Officer | OPT+S | $75.36 | 20,000 | $1,507,122 | 5,287 |
| 2025-11-08 00:30 | 2025-11-06 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $448.41 | 8,000 | $3,587,316 | 130 |
| 2025-11-07 00:00 | 2025-11-05 | LLY | ELI LILLY & Co | LILLY ENDOWMENT INC | 10% owner | SELL | $951.56 | 40,432 | $38,473,442 | 93,711,978 |
| 2025-11-07 00:00 | 2025-11-05 | LLY | ELI LILLY & Co | LILLY ENDOWMENT INC | 10% owner | SELL | $933.26 | 179,042 | $167,092,110 | 93,752,410 |
| 2025-11-07 02:12 | 2025-11-04 | ANTX | AN2 Therapeutics, Inc. | Eizen Joshua M | Officer | SELL | $1.14 | 2,819 | $3,214 | 177,353 |
| 2025-11-07 02:11 | 2025-11-04 | ANTX | AN2 Therapeutics, Inc. | Prior Stephen David | Officer | SELL | $1.14 | 765 | $872 | 65,548 |
| 2025-11-06 16:00 | 2025-11-05 | NVCT | Nuvectis Pharma, Inc. | Sanchez Juan | Director | BUY | $5.79 | 13,000 | $75,270 | 78,150 |
| 2025-11-06 16:00 | 2025-11-05 | NVCT | Nuvectis Pharma, Inc. | Kaplan Matthew L. | Director | BUY | $5.84 | 11,000 | $64,240 | 124,760 |
| 2025-11-07 03:41 | 2025-11-04 | HOWL | Werewolf Therapeutics, Inc. | MPM BioVentures 2014, L.P. | 10% owner | SELL | $1.22 | 242,890 | $295,791 | 5,904,720 |
| 2025-11-06 15:30 | 2025-11-05 | RLMD | RELMADA THERAPEUTICS, INC. | Ence Chuck | Officer | BUY | $2.20 | 136,000 | $299,200 | 403,931 |
| 2025-11-06 15:30 | 2025-11-05 | RLMD | RELMADA THERAPEUTICS, INC. | TRAVERSA SERGIO | Director, Officer | BUY | $2.20 | 272,500 | $599,500 | 1,272,500 |
| 2025-11-06 15:30 | 2025-11-05 | RLMD | RELMADA THERAPEUTICS, INC. | Shenouda Maged | Officer | BUY | $2.20 | 500,000 | $1,100,000 | 788,335 |
| 2025-11-06 15:30 | 2025-11-05 | RLMD | RELMADA THERAPEUTICS, INC. | Kelly Paul Edward | Director, Officer | BUY | $2.20 | 90,000 | $198,000 | 502,295 |
| 2025-11-06 20:21 | 2025-11-03 | VSTM | Verastem, Inc. | Paterson Dan | Director, Officer | SELL | $9.74 | 3,299 | $32,146 | 438,818 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.